Pharma’s Digital Pathology Build-Out; Part 2 – What It Means

 
• By Rachel Laing, Sophie Peltre, and Mark Ratner
  
Access
Users of digital pathology are positive clinical use cases can surmount issues around access • Source: Shutterstock

More from Market Access

More from In Vivo